Abstract
Psychiatric medications such as antidepressants, antipsychotics, and anticonvulsants are commonly prescribed by physicians for the off-label use of improving sleep. Reasons for preferential prescription of these medications over FDA-approved insomnia drugs may include a desire to treat concurrent sleep problems and psychiatric illness with a single medication, and/or an attempt to avoid hypnotic drugs due to their publicized side effects. However, there have been few large studies demonstrating the efficacy and safety of most off-label medications prescribed to treat insomnia. In addition, many of these medications have significant known side effect profiles themselves. Here we review the pertinent research studies published in recent years on antidepressant, antipsychotic, and anticonvulsant medications frequently prescribed for sleep difficulties. Although there have been few large-scale studies for most of these medications, some may be appropriate in the treatment of sleep issues in specific well-defined populations.
Similar content being viewed by others
References
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
Walsh JK, Schweitzer PK. Ten-year trends in the pharmacological treatment of insomnia. Sleep. 1999;22:371–5.
Walsh JK. Drugs used to treat insomnia in 2002: regulatory-based rather than evidence-based medicine. Sleep. 2004;27:1441–2.
Owens J, Rosen C, Mindell J, et al. Use of pharmacotherapy for insomnia in child psychiatry practice: a national survey. Sleep Med. 2010;11:692–700.
Mindell J, Emslie G, Blumer L, et al. Pharmacologic management of insomnia in children and adolescents: consensus statement. Pediatrics. 2006;117:1223–32.
Poceta J. Zolpidem ingestion, automatisms, and sleep driving: a clinical and legal case series. J Clin Sleep Med. 2011;7:632–8.
Rottach K, Schaner BM, Kirch M. Restless leg syndrome as side effect of second generation antidepressants. J Psychiatr Res. 2008;43:70–5.
Schweitzer P, et al. Drugs that disturb sleep and wakefulness. In: Kryger M, Roth T, Dement, editors. Principles and practice of sleep medicine. 5th ed. St Louis: Elsevier Saunders; 2012. p. 542.
Weber J, Siddiqui M, Wagstaff A. Low-dose doxepin: in the treatment of insomnia. CNS Drugs. 2010;24:713–20.
Kuntz R. Off-label prescribing of antidepressants and anxiolytics: an attorney's guide to psychoactive drugs. J Psychiatry Law. 1998;26:519–32.
Kramer S, McCall V. Off-label prescribing: 7 steps for safer, more effective treatment. Curr Psychiatry. 2006;5:15–28.
•• McCall W. Off-label use of prescription medications for insomnia: sedating antidepressants, antipsychotics, anxiolytics, and anticonvulsants. In: Sateia M, Buysse D, editors. Insomnia: diagnosis and treatment. London: Informa Healthcare; 2010. p. 397–409. This chapter presents a comprehensive review of the literature regarding the off-label use of psychiatric medications in treating sleep difficulties.
Dording C, Mischoulon D, Petersen T, et al. The pharmacologic management of SSRI-induced side effects: a survey of psychiatrists. Ann Clin Psychiatry. 2002;14:143–7.
Montgomery I, Oswald I, Morgan K, et al. Trazodone enhances sleep in subjective quality but not in objective duration. Br J Clin Pharmacol. 1983;16:139–44.
Yamadera H, Nakamura S, Suzuki H, et al. Effects of trazodone hydrochloride and imipramine on polysomnography in healthy subjects. Psychiatry Clin Neurosci. 1998;52:439–43.
Ware JC, Pittard JT. Increased deep sleep after trazodone use: a double-blind placebo-controlled study in healthy young adults. J Clin Psychiatry. 1990;51:18–22.
Mendelson WB. A review of the evidence for the efficacy and safety of trazodone in insomnia. J Clin Psychiatry. 2005;66:469–76.
Haffmans PMJ. The effects of trazodone on sleep disturbances included by brofaromine. Eur Psychiatry. 1999;14:167–71.
Nierenberg A, Adler LA, Peselow E, et al. Trazodone for antidepressant-associated insomnia. Am J Psychiatry. 1994;151:1069–72.
Burns M, Hoskowitz H, Jaffe J. A comparison of the effects of trazodone and amitriptyline on skills performance by geriatric subjects. J Clin Psychiatry. 1986;47:252–4.
Warrington SJ, Ankier SI, Turner P. An evaluation of possible interactions between ethanol and trazodone or amitriptyline. Br J Clin Pharmacol. 1984;18:549–57.
Saletu-Zyhlarz G, Abu-Bakr M, Anderer P, et al. Insomnia related to dysthymia: polysomnographic and psychometric comparison with normal controls and acute therapeutic trials with trazodone. Neuropsychobiology. 2001;44:139–49.
James S, Mendelson W. The use of trazodone as a hypnotic: a critical review. J Clin Psychiatry. 2004;65:752–5.
• Roth A, McCall W, Vaughn, Liguori A. Cognitive, psychomotor and polysomnographic effects of trazodone in primary insomniacs. J Sleep Res. 2011;20:552–8. Although trazodone is one of the most frequently prescribed off-label medications for insomnia, few studies have investigated its efficacy and safety for this indication. In this study, trazodone 50 mg produced significant impairments of short-term memory, verbal learning, equilibrium, and arm muscle endurance across time-points. Relative to placebo, trazodone was associated with fewer night-time awakenings, minutes of Stage 1 sleep and self-reports of difficulty sleeping.
Wichniak A, Wierzbicka A, Jernajczyk W. Patinets with insomnia and subthreshold depression show marked worsening of insomnia after discontinuation of sleep promoting medication. Prog Neuropsychopharmacol Biol Psychiatry. 2011;35:1671–6.
Sheehan D, Croft H, Gossen E, et al. Extended-release trazodone in major depressive disorder: a randomized, double-blind, placebo-controlled study. Psychiatry. 2009;6:20–33.
Calandre E, Morillas-Arques P, Molina-Barea R, et al. Trazodone plus pregabalin combination in the treatment of fibromyalgia: a 2-phase, 24-week, open-label uncontrolled study. BMC Musculoskelet Disord. 2011;12:95.
Morillas-Arques P, Rodriguez-Lopez C, Molina-Barea R, et al. Trazodone for the treatment of fibromyalgia: an open-label, 12-week study. BMC Musculoskelet Disord. 2010;11:204.
Camargos E, Pandolfi M, Freitas M, et al. Trazodone for the treatment of sleep disorders in dementia: an open-label, observational and review study. Arq Neuropsiquiatr. 2011;69:44–9.
Stein M, Kurth M, Sharkey K, et al. Trazodone for sleep disturbance during methadone maintenance: a double-blind, placebo-controlled trial. Drug Alcohol Depend. 2012;120:65–73.
Kupfer DJ, Spiker DG, Coble P, et al. Amitriptyline and EEG sleep in depressed patients: I. Drug effect Sleep. 1978;1:149–59.
Doerr J, Spiegelhalder K, Petzold F, et al. Impact of escitalopram on nocturnal sleep, day-time sleepiness, and performance compared to amitriptyline: a randomized, double-blind, placebo-controlled study in healthy male subjects. Pharmacopsychiatry. 2010;43:166–73.
Ware M, Fitzcharles M, Joseph L, et al. The effects of nabilone on sleep in fibromyalgia: results of a randomized controlled trial. Anesth Analg. 2010;110:604–10.
Roth T, Rogowski R, Hull S, et al. Efficacy and safety of doxepin 1 mg, 3 mg, and 6 mg in adults with primary insomnia. Sleep. 2007;30:1555–61.
•• Krystal A, Lankford A, Durrence HH, et al. Efficacy and safety of doxepin 3 and 6 mg in a 35-day sleep laboratory trial in adults with chronic primary insomnia. Sleep. 2011;34:1433–42. Five weeks of nightly administration of doxepin 3 mg and 6 mg to adults with chronic primary insomnia resulted in significant and sustained improvements in sleep maintenance and early morning awakenings.
•• Krystal A, Durrence HH, Scharf M. Efficacy and safety of doxepin 1 mg and 3 mg in a 12-week sleep laboratory and outpatient trial of elderly subjects with chronic primary insomnia. Sleep. 2010;33:1553–61. Doxepin 1 mg and 3 mg administered nightly to elderly chronic insomnia patients for 12 weeks resulted in significant and sustained improvements in most endpoints, without evidence of next-day residual sedation or other significant adverse effects. Doxepin also demonstrated improvements in both patient- and physician-based ratings of global insomnia outcome.
•• Lankford A, Rogowski R, Essink B, et al. Efficacy and safety of doxepin 6 mg in a 4-week outpatient trial of elderly adults with chronic primary insomnia. Sleep Med. 2012;13:133–8. Elderly adults meeting DSM-IV-TR criteria for primary insomnia were randomized to 4 weeks of nightly treatment with either doxepin 6 mg or placebo. Doxepin 6 mg produced significant improvements in sleep maintenance, sleep duration, and sleep quality endpoints that were sustained throughout the trial.
Ruigt GSF, Kemp B, Groenhout CM, et al. Effect of the antidepressant Org 3770 on human sleep. Eur J Clin Pharmacol. 1990;38:551–4.
Aslan S, Isik E, Cosar B. The effects of mirtazapine on sleep: a placebo controlled, double-blind study in young healthy volunteers. Sleep. 2002;25:677–9.
Perez D, Loprinzi D, Barton DL. Pilot evaluation of mirtazapine for the treatment of hot flashes. J Support Oncol. 2004;2:50–6.
Wingen M, Bothmer J, Langer S, et al. Actual driving performance and psychomotor function in healthy subjects after acute and subchronic treatment with escitalopram, mirtazapine, and placebo: a crossover trial. J Clin Psychiatry. 2005;66:436–43.
Shen J, Hossain N, Streiner D, et al. Excessive daytime sleepiness and fatigue in depressed patients and therapeutic response of a sedating antidepressant. J Affect Disord. 2011;134:421–6.
Shen J, Moller H, Wang X, et al. Mirtazapine, a sedating antidepressant, and improved driving safety in patients with major depressive disorder: a prospective, randomized trial of 28 patients. J Clin Psychiatry. 2009;70:370–7.
Dolev Z. Case series of perimenopausal women with insomnia treated with mirtazapine followed by prolonged-release melatonin add-on and monotherapy. Arch Womens Ment Health. 2011;14:269–73.
Cohrs S, Rodenbeck A, Guan Z, et al. Sleep-promoting properties of quetiapine in healthy subjects. Psychopharmacology. 2004;174:421–9.
Wiegand M, Landry F, Bruckner T, et al. Quetiapine in primary insomnia: a pilot study. Psychopharmacology. 2008;196:337–8.
Nanda F, Singer C. Placebo-Controlled Trial of Quetiapine for Sleep Disturbance in Dementia and MCI. 16 ed. 2008;A126.
Cates M, Jackson C, Feldman J, et al. Metabolic consequences of using low-dose quetiapine for insomnia in psychiatric patients. Community Ment Health J. 2009;45:251–4.
Dolder C, McKinsey J. Quetiapine for sleep in patients with dementia. Consult Pharm. 2010;25:676–9.
Tassniyom K, Paholpak S, Tassniyom S, et al. Quetiapine for primary insomnia: a double blind, randomized controlled trial. J Med Assoc Thai. 2010;93:729–34.
Golubchik P, Sever J, Weizman A. A low-dose quetiapine for adolescents with autistic spectrum disorder and aggressive behavior: open-label trial. Clin Neuropharmacol. 2011;34:216–9.
Stein D, Bandelow B, Merideth C, et al. Efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in patients with generalized anxiety disorder: an analysis of pooled data from 3 8-week placebo-controlled studies. Hum Psychopharmacol. 2011;26:614–28.
Bauer M, El-Khalili N, Datto C, et al. A pooled analysis of 2 randomized, placebo-controlled studies of extended release quetiapine fumarate adjunctive to antidepressant therapy in patients with major depressive disorder. J Affect Disord. 2010;127:19–30.
Foldvary-Schaefer N, De Leon Sanchez I, Karafa M, et al. Gabapentin increases slow-wave sleep in normal adults. Epilepsia. 2002;43:1493–7.
Karam-Hage M, Brower K. Open pilot study of gabapentin versus trazodone to treat insomnia in alcoholic outpatients. Psychiatry Clin Neurosci. 2003;57:542–4.
Furieri F, Nakamura-Placios E. Gabapentin reduces alcohol consumption and craving: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2007;68:1691–700.
Arnold LM, Goldenberg D, Stanford S, et al. Gabapentin in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled, multicenter trial. Arthritis Rheum. 2007;56:1336–44.
Hahn K, Arendt G, Braun J, et al. A placebo-controlled trial of gabapentin for painful HIV-associated sensory neuropathies. J Neurol. 2004;251:1260–6.
Rice A, Maton S, Postherpetic Neuralgia Study Group. Gabapentin in postherpetic neuralgia: a randomized, double blind, placebo controlled study. Pain. 2001;94:215–24.
Backonja M. Gabapentin monotherapy for the symptomatic treatment of painful neuropathy: a multicenter, double-blind, placebo-controlled trial in patients with diabetes mellitus. Epilepsia. 1990;40(Suppl):S57–9.
Gordh T, Stubhaug A, Jenson T, et al. Gabapentin in traumatic nerve injury pain: a randomized, double-blind, placebo-controlled, cross-over, multi-center study. Pain. 2008;138:255–66.
Lo H, Yang C, Lo H, et al. Treatment effects of gabapentin for primary insomnia. Clin Neuropharmacol. 2010;33:84–90.
Yurcheshen M, Guttuso TJ, McDermott M, et al. Effects of gabapentin on sleep in menopausal women with hot flashes as measured by a Pittsburgh sleep quality index factor scoring model. J Womens Health. 2009;18:1355–60.
Myrick H, Malcolm R, Randall P. A double-blind trial of gabapentin vs lorazepam in the treatment of alcohol withdrawal. Alcohol Clin Exp Res. 2009;33:1582–8.
Hindmarch I, Dawson J, Stanley N. A double-blind study in healthy volunteers to assess the effects on sleep of pregabalin compared with alprazolam and placebo. Sleep. 2005;28:187–93.
Arnold LM, Russell I, Diri E, et al. A 14-week, randomized, double-blinded, placebo-controlled monotherapy trial of pregabalin in patients with fibromyalgia. J Pain. 2008;9:792–805.
Freeman R, Durso-Decruz E, Emir B. Efficacy, safety, and tolerability of pregabalin treatment for painful diabetic peripheral neuropathy: findings from 7 randomized, controlled trials across a range of doses. Diabetes Care. 2008;31:1448–54.
Mease P, Russell I, Arnold LM, et al. A randomized, double-blind, placebo-controlled, phase III trial of pregabalin in the treatment of patients with fibromyalgia. J Rheumatol. 2008;35:502–14.
Siddall P, Cousins M, Otte A, et al. Pregabalin in central neuropathic pain associated with spinal cord injury: a placebo-controlled trial. Neurology. 2006;67:1792–800.
Russell I, Crofford L, Leon T. The effects of pregabalin on sleep disturbance symptoms among individuals with fibromyalgia syndrome. Sleep Med. 2009;10:604–10.
• Pauer L, Winkelmann A, Arsenault P, et al. An international, randomized, double-blind, placebo-controlled, phase III trial of pregabalin monotherapy in treatment of patients with fibromyalgia. J Rheumatol. 2011;38:2643–52. This international, multicenter, double-blind, placebo-controlled trial randomly assigned 747 patients with fibromyalgia to placebo or 300, 450, or 600 mg/day pregabalin twice daily for 14 weeks. All pregabalin doses demonstrated superiority to placebo on the Medical Outcomes Study-Sleep Scale Sleep Disturbance subscale and the Sleep Quality diary.
• Montgomery S, Herman B, Schweizer E, et al. The efficacy of pregabalin and benzodiazepines in generalized anxiety disorder presenting with high levels of insomnia. Int Clin Psychopharmacol. 2009;24:214–22. Pooled data from 6 double-blind, placebo-controlled, 4- to 6-week trials of outpatients with generalized anxiety disorder found that pregabalin was well tolerated and improved overall anxiety symptoms, while specifically improving insomnia in patients with generalized anxiety disorder presenting with high levels of concurrent insomnia.
Zammit GK, McNabb LJ, Caron J, et al. Efficacy and safety of eszopiclone across 6-weeks of treatment for primary insomnia. Curr Med Res Opin. 2004;20:1979–91.
Roth T, Soubrane C, Titeux L, et al. Efficacy and safety of zolpidem-MR: a double-blind, placebo-controlled study in adults with primary insomnia. Sleep Med. 2006;7:397–406.
Disclosure
C. McCall: none; W. V. McCall: consultant for Sunovion.
Author information
Authors and Affiliations
Corresponding authors
Rights and permissions
About this article
Cite this article
McCall, C., McCall, W.V. What Is the Role of Sedating Antidepressants, Antipsychotics, and Anticonvulsants in the Management of Insomnia?. Curr Psychiatry Rep 14, 494–502 (2012). https://doi.org/10.1007/s11920-012-0302-y
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11920-012-0302-y